Orris

Essay on Discuss genes in neoplasia.

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive content from multiple authoritative textbooks. Let me compile the full essay.

Genes in Neoplasia

Introduction

Cancer arises from a fundamental disruption of the genetic programs that govern normal cell growth, differentiation, and death. Neoplastic transformation is not a single-step event but a multi-hit process in which mutations accumulate across four broad classes of regulatory genes: proto-oncogenes, tumor suppressor genes, DNA repair genes, and genes regulating apoptosis. Understanding these categories is essential to understanding the molecular basis of cancer.

1. Proto-Oncogenes and Oncogenes

Proto-oncogenes are normal cellular genes that encode proteins governing cell growth, proliferation, and differentiation — growth factors, growth factor receptors, signal transduction proteins, transcription factors, and cell cycle regulators. When mutated or overexpressed, they become oncogenes whose protein products (oncoproteins) drive unregulated cell proliferation. The defining feature of oncogene mutations is that they are gain-of-function — a single mutant allele is sufficient to promote transformation (dominant effect).

Classes of Proto-oncogene Products

Proto-oncogenes encode proteins across several functional categories (Basic Medical Biochemistry, 6e):
ClassProto-oncogeneActivation MechanismAssociated Tumor
Growth factorssis (PDGF β-chain)OverexpressionGlioma
Growth factor receptorserb-B2 (HER2)AmplificationBreast carcinoma
Signal transducersRASPoint mutationMany carcinomas
Transcription factorsMYCTranslocation / amplificationBurkitt lymphoma, neuroblastoma
Cell cycle regulatorsCyclin D1Amplification / translocationBreast, lymphoid tumors
Tyrosine kinasesABLTranslocation (fusion)CML (Philadelphia chromosome)

Mechanisms of Oncogene Activation

Four major mechanisms convert a proto-oncogene into an oncogene (Harper's Illustrated Biochemistry, 32e; Basic Medical Biochemistry, 6e):
  1. Point Mutation — The classic example is RAS. RAS encodes a small GTPase involved in the MAP kinase and adenylyl cyclase signalling pathways. A single point mutation abolishes its intrinsic GTPase activity, leaving RAS permanently bound to GTP and constitutively active. Cells are locked in continuous proliferative signalling. RAS mutations are found in ~30% of all human cancers.
  2. Chromosomal Translocation — A segment of one chromosome is repositioned adjacent to a strong promoter or enhancer on another chromosome.
    • Burkitt lymphoma: The c-MYC proto-oncogene (chromosome 8) is translocated to chromosome 14, placing it under the control of the immunoglobulin heavy-chain gene enhancer. The result is massive overexpression of the MYC transcription factor and uncontrolled B-cell proliferation.
    • Chronic myelogenous leukemia (CML): A reciprocal translocation between chromosomes 9 and 22 (the Philadelphia chromosome) fuses the BCR gene on chromosome 22 with the ABL tyrosine kinase gene on chromosome 9. The BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives the Ras/MAP kinase pathway incessantly, causing leukaemic proliferation. This fusion protein is the target of the drug imatinib (Gleevec).
  3. Gene Amplification — Multiple copies of a proto-oncogene are produced in a single cell, generating increased amounts of the growth-promoting protein.
    • N-MYC amplification occurs in neuroblastoma (poor prognosis).
    • HER2/neu (erb-B2) amplification occurs in ~20% of breast carcinomas and confers susceptibility to trastuzumab therapy.
    • Amplified regions may be visible cytogenetically as homogeneously staining regions (HSRs) or extrachromosomal double-minute chromosomes.
  4. Promoter/Enhancer Insertion — Retroviruses insert their long terminal repeat (LTR) sequences near proto-oncogenes, activating transcription. A viral promoter upstream of MYC, for example, drives its overexpression and cell transformation.

2. Tumor Suppressor Genes

Tumor suppressor genes (TSGs) encode proteins that restrain cell growth, promote differentiation, induce apoptosis, or maintain DNA integrity. Unlike oncogenes, TSG mutations operate in a loss-of-function, recessive manner — both alleles must be inactivated for the growth-inhibitory effect to be lost (Knudson's "two-hit hypothesis"). However, one inactivated allele is inherited in hereditary cancer syndromes, requiring only a somatic "second hit" to cause disease.

The Retinoblastoma Gene (RB1) — The Prototype

The RB gene, located on chromosome 13q14, was the first tumor suppressor gene discovered. The RB protein (pRb) is the master regulator of the G1/S cell cycle checkpoint (Robbins, Cotran & Kumar Pathologic Basis of Disease):
  • In quiescent cells, pRb is hypophosphorylated and bound to the E2F family of transcription factors, inhibiting their activity and blocking S-phase entry.
  • Growth factor stimulation induces synthesis of cyclin D, which partners with CDK4/CDK6. The cyclin D–CDK4/6 complex phosphorylates pRb, releasing E2F.
  • Free E2F then drives transcription of genes needed for S-phase entry: cyclin E, cyclin A, and DNA replication machinery.
  • Loss of RB removes this critical "brake," allowing unrestrained E2F activity and perpetual cell cycle progression.
Hereditary retinoblastoma: Germline mutation of one RB1 allele, followed by somatic loss of the second allele (often by deletion of 13q), leads to bilateral, multifocal retinoblastoma in children. In sporadic retinoblastoma, both somatic mutations occur in the same cell.
RB pathway mutations are found in virtually all human cancers through direct RB1 deletion/mutation, or indirectly through overexpression of D cyclins, CDK4 amplification, or loss of CDK inhibitors such as p16/INK4a (CDKN2A).

TP53 — "Guardian of the Genome"

TP53 is the most frequently mutated gene in human cancer (~50% of all cancers), earning the name "guardian of the genome" (Robbins, Cotran & Kumar Pathologic Basis of Disease). The p53 protein is activated by a wide array of cellular stresses:
  • DNA damage (UV radiation, ionising radiation, carcinogens)
  • Oncogene activation (e.g., overactivated RAS triggers ARF, which stabilises p53 by inhibiting MDM2)
  • Hypoxia, ribonucleotide depletion
Under normal conditions, p53 levels are kept low by MDM2 (an E3 ubiquitin ligase that targets p53 for proteasomal degradation). When DNA damage occurs, p53 is stabilised and activated, leading to:
  1. Cell cycle arrest — p53 transcriptionally activates p21 (CDKN1A), a CIP/KIP family CDK inhibitor that blocks cyclin D–CDK4/6 and cyclin E–CDK2 complexes, halting the cell cycle at G1/S to allow DNA repair.
  2. DNA repair — p53 upregulates DNA repair genes (GADD45) and promotes nucleotide excision repair.
  3. Apoptosis — If damage is irreparable, p53 induces apoptosis by upregulating pro-apoptotic genes including BAX, PUMA, and NOXA, shifting the BCL2 family balance toward cell death.
  4. Senescence — Persistent p53 activation can trigger permanent cell cycle arrest (senescence).
Li-Fraumeni syndrome: Germline TP53 mutation causes a hereditary cancer predisposition syndrome with a high lifetime risk of sarcomas, brain tumours, breast cancer, adrenocortical carcinoma, and leukaemia. When TP53 is lost, cells with damaged DNA survive, accumulate further mutations, and progress to malignancy.

APC — Gatekeeper of Colonic Neoplasia

The APC (adenomatous polyposis coli) gene on chromosome 5q21 is mutated in ~70–80% of colorectal carcinomas (Robbins, Cotran & Kumar Pathologic Basis of Disease). APC is a component of the Wnt/β-catenin signalling pathway:
  • Normally, APC forms a "destruction complex" with AXIN and GSK-3β that phosphorylates β-catenin, targeting it for proteasomal degradation.
  • Wnt signalling (or APC loss) disrupts this complex, allowing β-catenin to accumulate and translocate to the nucleus.
  • Nuclear β-catenin complexes with TCF transcription factor to drive expression of growth-promoting genes: MYC and cyclin D1.
  • Loss of APC therefore mimics constitutive Wnt stimulation, resulting in persistent proliferative signalling.
Familial adenomatous polyposis (FAP): Germline APC mutation leads to thousands of colonic adenomatous polyps in adolescence/early adulthood, with near-certain progression to colorectal cancer by age 40 unless prophylactic colectomy is performed.

PTEN

PTEN is a phosphatase that opposes PI3K/AKT/mTOR signalling — a major growth and survival pathway. PTEN dephosphorylates PIP3 to PIP2, reducing AKT activity. Loss of PTEN leads to constitutive AKT activation, driving cell survival, protein synthesis, and proliferation. PTEN is one of the most commonly deleted TSGs across cancers and is central to Cowden syndrome (hereditary hamartoma–breast cancer syndrome).

NF1, NF2 and BRCA1/2

  • NF1 (neurofibromatosis type 1): Encodes neurofibromin, a RAS-GAP (GTPase-activating protein). Loss of NF1 impairs GTP hydrolysis by RAS, causing prolonged RAS activation. NF1 mutations drive neurofibromas, malignant peripheral nerve sheath tumours, and other cancers.
  • NF2: Encodes merlin, which links cell surface adhesion to intracellular growth signals. Merlin loss leads to meningiomas and schwannomas.
  • BRCA1/BRCA2: These TSGs encode proteins involved in homologous recombination DNA repair. Germline mutations in BRCA1 or BRCA2 confer lifetime breast cancer risks of 60–85% and elevated ovarian cancer risk. BRCA-deficient cells cannot repair double-strand DNA breaks by homologous recombination and are exquisitely sensitive to PARP inhibitors (synthetic lethality).

3. DNA Repair Genes

DNA repair genes constitute a third functional category of cancer genes. Their products do not directly stimulate or inhibit growth — instead, they maintain the integrity of the genome. Loss of DNA repair capacity leads to a "mutator phenotype": an accelerated rate of mutation in growth-regulatory genes, hastening transformation. Since DNA repair genes follow a loss-of-function pattern like TSGs, they are sometimes called "caretaker" genes (Basic Medical Biochemistry, 6e; Robbins, Cotran & Kumar):
  1. Mismatch Repair (MMR) genes — HNPCC/Lynch syndrome: MLH1, MSH2, MSH6, and PMS2 encode the mismatch repair machinery that corrects errors in DNA replication (insertion/deletion loops and base mismatches). Germline mutation in any of these genes causes hereditary non-polyposis colorectal cancer (HNPCC/Lynch syndrome). MMR-deficient tumours exhibit microsatellite instability (MSI) — length variations at simple nucleotide repeats throughout the genome. These tumours are hypermutated and, importantly, are highly responsive to immune checkpoint inhibitors (anti-PD-1 therapy).
  2. Nucleotide Excision Repair (NER) — Xeroderma pigmentosum: XPA–XPG genes encode NER proteins that excise bulky DNA adducts and UV-induced photoproducts (pyrimidine dimers). Inherited mutations cause xeroderma pigmentosum, with extreme UV photosensitivity and up to a 1,000-fold increased risk of skin cancer.
  3. Base Excision Repair — MUTYH: Biallelic mutation of MUTYH causes MUTYH-associated polyposis (MAP), a form of colonic polyposis arising from defective correction of 8-oxo-dG:adenine mismatches caused by oxidative DNA damage.
  4. Homologous Recombination — BRCA1/2, PALB2: As noted above, loss of homologous recombination predisposes to breast and ovarian cancer and creates sensitivity to PARP inhibitors.

4. Genes Regulating Apoptosis

Resistance to programmed cell death is a central hallmark of cancer. Several oncogenes and tumour suppressor genes converge on the apoptosis machinery:
  • BCL2 (proto-oncogene): In follicular lymphoma, the t(14;18) translocation places BCL2 under the immunoglobulin heavy-chain enhancer, causing massive BCL2 overexpression. BCL2 prevents mitochondrial outer membrane permeabilisation, blocking cytochrome c release and protecting cancer cells from apoptosis.
  • BAX, PUMA, BIM (pro-apoptotic): These BCL2 family members are frequently down-regulated or mutated in cancer, tipping the balance toward survival.
  • TP53: As discussed, p53 induces apoptosis by upregulating BAX and PUMA. Loss of TP53 is a major mechanism of apoptosis evasion.
  • IAPs (inhibitor of apoptosis proteins): Frequently overexpressed in cancer, these proteins block caspase-9 activation downstream of mitochondrial permeabilisation.

5. Telomere Maintenance Genes and Epigenetic Regulators

Telomeres and TERT

Somatic cells normally undergo replicative senescence as telomeres shorten with each division. In cancer cells, the telomerase reverse transcriptase (TERT) is reactivated, restoring telomere length and conferring replicative immortality. TERT promoter mutations (among the most common non-coding mutations in cancer) drive telomerase expression in melanoma, glioblastoma, and bladder cancer.

Epigenetic Modifier Genes

Somatic mutations in genes encoding chromatin-remodelling and DNA methylation machinery constitute an expanding class of cancer genes:
  • IDH1/IDH2 mutations: Gain-of-function point mutations in isocitrate dehydrogenase produce the oncometabolite 2-hydroxyglutarate, which competitively inhibits α-ketoglutarate–dependent dioxygenases, including the TET family of DNA demethylases. This leads to CpG island hypermethylation (the "CpG island methylator phenotype," CIMP) and silencing of tumour suppressor genes, seen in gliomas and acute myeloid leukaemia (AML) (Robbins, Cotran & Kumar).
  • DNMT3A, TET2, EZH2, ARID1A: Mutations in DNA methyltransferases, histone methyltransferases (PRC2/EZH2), and SWI/SNF chromatin remodelling complexes are common drivers in haematologic malignancies and multiple carcinomas.

6. The Multistep Model of Carcinogenesis — Integration of Gene Mutations

No single gene mutation suffices to produce cancer. Transformation requires an accumulation of mutations across multiple classes of regulatory genes — the so-called multi-hit model. The best characterised example is colorectal carcinogenesis (the Vogelstein model):
StepGenetic EventFunctional Consequence
Normal epithelium → Aberrant crypt fociLoss of APC (chr 5q)Disrupted Wnt signalling; ↑ proliferation
Early adenomaDNA hypomethylationGene instability
Intermediate adenomaKRAS mutationConstitutive RAS activation
Late adenomaLoss of SMAD2/4 (chr 18q); Loss of DCCDisrupted TGF-β signalling
CarcinomaLoss of TP53 (chr 17p)Loss of apoptosis and G1 checkpoint
MetastasisAdditional mutations in invasion/metastasis genesMMPs, E-cadherin loss
This paradigm illustrates that tumourigenesis is a clonal evolutionary process in which successive genetic alterations confer a selective growth advantage, with each step corresponding to a clinically recognisable histological stage. The specific genes may differ by tumour type, but the principle — progressive accumulation of oncogene activations and TSG inactivations — is universal.

7. Hereditary Cancer Syndromes — Germline Mutations

Germline mutations in tumour suppressor genes cause hereditary cancer predisposition syndromes:
SyndromeGeneChromosomeTumour Spectrum
Familial retinoblastomaRB113q14Retinoblastoma, osteosarcoma
Li-Fraumeni syndromeTP5317p13Sarcoma, breast cancer, brain tumours, adrenocortical carcinoma
Familial adenomatous polyposisAPC5q21Colorectal carcinoma
Lynch syndrome (HNPCC)MLH1, MSH2, MSH6, PMS2VariousColorectal, endometrial, ovarian cancer
Hereditary breast/ovarian cancerBRCA1, BRCA217q, 13qBreast, ovarian, prostate cancer
Cowden syndromePTEN10q23Breast, thyroid, endometrial cancer
Von Hippel-Lindau diseaseVHL3p25Clear cell renal carcinoma, haemangioblastoma
Neurofibromatosis type 1NF117q11Neurofibromas, MPNST, GIST
MEN2A/2BRET (activating)10q11Medullary thyroid carcinoma, phaeochromocytoma
These syndromes demonstrate that a single inherited mutation predisposes but does not inevitably cause cancer — additional somatic mutations (the "second hit") are required.

Conclusion

Neoplasia is, at its core, a genetic disease of somatic cells (with hereditary predispositions in a subset of cases). The four cardinal gene classes — proto-oncogenes/oncogenes, tumour suppressor genes, DNA repair genes, and apoptosis-regulating genes — collectively govern the balance between cell proliferation and cell death. Oncogenes act as dominant accelerators (gas pedals), while tumour suppressor genes are recessive brakes. DNA repair genes maintain the fidelity of replication, and apoptosis genes determine the fate of damaged cells. Cancer arises when mutations in enough of these gene classes accumulate within a single clonal lineage to override normal homeostatic mechanisms, conferring the hallmarks of cancer: self-sufficiency in growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replication, angiogenesis, invasion, and metastasis. This molecular framework not only explains tumour biology but has directly enabled targeted therapies — imatinib for BCR-ABL, trastuzumab for HER2, PARP inhibitors for BRCA-deficient cancers, anti-PD-1 for MMR-deficient tumours — that have transformed oncological practice.
Sources:
  • Robbins, Cotran & Kumar — Pathologic Basis of Disease, 10th ed., Chapter 7 (Neoplasia)
  • Basic Medical Biochemistry: A Clinical Approach, 6e, Chapter 17 (Molecular Biology of Cancer)
  • Harper's Illustrated Biochemistry, 32nd ed., Chapter 56 (Cancer: An Overview)
  • Thompson & Thompson Genetics and Genomics in Medicine, 9th ed., Chapter 7 (Tumour Suppressor Genes)
This is a shared conversation. Sign in to Orris to start your own chat.